Prof. Fuad Fares completed his DSc studies in the Faculty of Medicine, Technion-Israel Institute of Technology, and postdoctoral studies in the Department of Molecular Biology and Pharmacology at the School of Medicine, Washington University, St. Louis Missouri. He founded and directs the Department of Molecular Genetics at Carmel Medical Center and is associate professor in the Department of Human Biology, University of Haifa. He has published more than 75 papers in reputed journals and serves as a member of the Israel Council for Higher Education.
Prof. Fuad Fares is founder and chief scientific officer of biomedical start-up PROLOR BIOTECHNOLOGY, which has genetically engineered a platform that prolongs the lifespan and efficancy of therapeutic proteins in treating deficiencies.
Prof. Fuad Fares with Dr. Lital Sharvit are in the advanced stages of research leading toward the development of a novel treatment for pancreatic cancer, based on the properties of a mushroom-derived compound that they discovered in a species endemic to Israel.Carmel established CanCurX Ltd. to advance and commercialize this technology.